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OBJECTIVES: In daily practice many Type 2 Diabetes Mellitus
(T2DM-)patients discontinue treatment. Therefore, the aim of
this study was to investigate the determinants of (non-)
persistence with oral antidiabetic drugs (OADs) in daily clinical
practice. METHODS: From the PHARMO record linkage
system, comprising among others linked drug-dispensing, and
hospital data for >2.3 million subjects in The Netherlands, new
users of OADs were identiﬁed in the period 1999–2005. Patients
with 1 year of follow-up, were included in the study-cohort.
Persistence with OAD-treatment in the ﬁrst year of therapy
was determined using the method of Catalan. Potential determi-
nants of (non-)persistence included patient-characteristics, type
of initial OAD-therapy, and cardiovascular co-morbidity.
RESULTS: The study included 33,299 new users of OADs. One
year after start, 42% of new T2DM-patients had stopped using
any OAD. The risk of non-persistence was decreased with male
gender (HR: 0.97; 95% CI: 0.94–1.00), and cardiovascular drug
use (HR: 0.91; 95% CI: 0.86–0.97). Regarding age, compared to
patients 76 years, the age-group 55–75 years had a 16% lower
risk, and the age-group 30–44 years had a 32% increased risk of
non-persistence. Patients starting on combined metformin + SU
had a lower risk of non-persistence with any OAD; compared to
patients starting on metformin monotherapy, the risk was 23%
lower (HR: 0.77; 95% CI: 0.70–0.85). The risk of non-
persistence was increased with a specialist as ﬁrst prescriber (HR:
1.20; 95% CI: 1.15–1.26), higher initial daily dose (HR: 1.09;
95% CI: 1.00–1.22), and higher initial daily dosing frequency
(HR: 1.10; 95% CI: 1.02–1.20). CONCLUSION: In daily
clinical practice about 40% of new T2DM-patients stop OAD-
therapy within one year. Determinants of stopping OAD-
medication were male gender, age-group, specialist as ﬁrst
prescriber, dosing, cardiovascular drug-use, and type of initial
OAD-treatment.
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OBJECTIVES: To determine if patients enrolled in a pharmacist–
provided disease management program have improved clinical
and PROs (humanistic and economic). METHODS: This
program was developed and implemented at three independent
community pharmacy sites. A prospective pre-post design was
used. Adult patients with Type 2 DM and HbA1c levels > 6%
were included. Study measures: 1) Clinical: glycemic control,
blood pressure, random blood glucose value, and body mass
index (BMI); 2) Humanistic: Diabetes Knowledge Test (DKT),
diabetes speciﬁc quality-of-life (D-39), and self-monitoring of
blood glucose (SMBG); 3) Economic: diabetes-related sick days
and ER visits; and 4) HEDIS process measures: incidence of
annual eye and foot exams. Data were collected at baseline, 3
months, and between 6–9 months and analyzed using SPSS v14.
Descriptive statistics and repeated measures ANOVA were used.
Comparisons were made with 2005 NCQA national averages.
RESULTS: Sixty patients were enrolled. Most were women
(63.3%) and the mean age was 62.43 years (12.09). At study
termination, 73% of patients achieved optimal glycemic control
compared to 66% at baseline. Patients knowledge scores
improved from 30.07 to 33.08 (p = 0.003). Patients experienced
better control of their diabetes as was measure by D-39
(p = 0.02). The frequency of SMBG, increased from 1.83 to 2.17
tests per day (p = 0.045). The mean number of sick days and ER
visits reported was 0.13 days (0.46) and 0.03 visits (0.16) at
baseline, and 0.00 days (0.00) and 0.05 visits (0.32) at study
termination. Percentage of patients receiving an eye exam and
annual foot exam increased from 79.7% to 90.0%, and from
35.6% to 55.0%, respectively. CONCLUSION: Comparisons
with NCQA data indicated that patients were relatively well
controlled. Pharmacists’ interventions helped improve and main-
tain increased knowledge regarding diabetes. As a result of this
heightened knowledge, patients were able to stave off disease
progression during the study period.
PDB71
PILOT STUDY OF CLINICIAN ATTITUDESTO PUMPTHERAPY:
INTERNATIONAL DIFFERENCES ANDTHE NEED FOR A
GREATER UNDERSTANDING OFTHE PATIENT PERSPECTIVE
Reaney M1, Barnard K2, Skinner TC3, Speight J1
1AHP Research Ltd, Uxbridge, Middlesex, UK, 2University of
Southampton, Southampton, UK, 3University of Wollongong,
Wollongong, NSW, Australia
OBJECTIVES: To identify and survey health care professionals
(HCPs) attitudes to insulin pump therapy (CSII). METHODS:
Eight specialists were interviewed to explore the attitudes and
beliefs about CSII. Responses were analysed thematically and
used to inform the design of a new 22-item questionnaire: the
Attitudes to Pump Therapy (APT) Survey. The APT was pilot-
tested among 95 HCPs (54% male; 75.5% diabetologists/DSNs,
13.8% general practitioners) at the International Diabetes Fed-
eration (IDF) conference, 2006. Results were analysed using
non-parametric statistics with bonferroni correction. RESULTS:
Analyses of interview data identiﬁed 9 themes: biomedical, per-
ceived control of care/diabetes, technology, quality of life, ﬁnan-
cial resources, training, education & support, suitability, and
evidence-base. Items were designed to reﬂect these themes
with responses scored on a 5-point Likert scale (strongly
agree—strongly disagree). No statistically signiﬁcant differences
were found by gender, HCP speciality, country (and continent) of
origin or proportion of patients using CSII. Most notable differ-
ences were found in relation to gross domestic product (GDP)
and the potential for pump therapy to achieve tight blood glucose
control (lower GDP = more agreement: p = 0.001), and result
in diabetic ketoacidosis (DKA) (lower GDP = less agreement:
p < 0.005). Ranked mean scores showed a split between
biomedical/clinical items (N = 11) and items concerned with
patient experience (N = 11). Attitudes about biomedical/clinical
issues were generally clear (i.e. for 7/11 items, the mean score
was “agree”) but less decisive about patient experience (i.e. for
8/11 items, the mean score was “neither agree nor disagree”).
CONCLUSION: Few subgroup differences existed, but those
that did may be explained by lack of access to treatment (directly
corresponding to GDP). Clinicians’ were generally clear in their
attitudes regarding biomedical aspects but less so regarding
patient experience. Research focusing on patient-reported out-
comes is likely to offer clinicians a greater understanding of the
patients’ perspective of insulin pump therapy.
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